Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - OtherShares IssuedShares OutstandingShares Outstanding
Ratios

Centessa Pharmaceuticals (CNTA) Accumulated Depreciation & Amortization (2021 - 2026)

Centessa Pharmaceuticals has reported Accumulated Depreciation & Amortization over the past 5 years, most recently at $921000.0 for Q4 2025.

  • Quarterly Accumulated Depreciation & Amortization fell 2.23% to $921000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $921000.0 through Dec 2025, down 2.23% year-over-year, with the annual reading at $921000.0 for FY2025, 2.23% down from the prior year.
  • Accumulated Depreciation & Amortization was $921000.0 for Q4 2025 at Centessa Pharmaceuticals, up from $680000.0 in the prior quarter.
  • Over five years, Accumulated Depreciation & Amortization peaked at $942000.0 in Q4 2024 and troughed at $28000.0 in Q1 2022.
  • The 5-year median for Accumulated Depreciation & Amortization is $326000.0 (2023), against an average of $398117.6.
  • Year-over-year, Accumulated Depreciation & Amortization skyrocketed 518.32% in 2023 and then fell 9.58% in 2025.
  • A 5-year view of Accumulated Depreciation & Amortization shows it stood at $34000.0 in 2021, then skyrocketed by 285.29% to $131000.0 in 2022, then skyrocketed by 518.32% to $810000.0 in 2023, then grew by 16.3% to $942000.0 in 2024, then dropped by 2.23% to $921000.0 in 2025.
  • Per Business Quant, the three most recent readings for CNTA's Accumulated Depreciation & Amortization are $921000.0 (Q4 2025), $680000.0 (Q3 2025), and $443000.0 (Q2 2025).